肠易激综合征临床诊疗缺口与外周内脏传入调节的未来治疗潜力
本综述评估了肠易激综合征(IBS)治疗中未被满足的需求,重点在于安全止痛。文章回顾了内脏传入功能生理学及背根神经节(DRG)细胞体受体,并基于啮齿类内脏高敏感模型和IBS随机对照试验,总结了靶向DRG受体的药理方法证据。结论支持开发外周限制性新药以减少IBS内脏疼痛。
要点
- IBS治疗最大需求是安全有效地缓解疼痛。
- 靶向DRG受体(如α-2肾上腺素能、生长抑素-SS2、5-HT3等)是潜在新策略。
- 外周限制性神经调节剂可能成为中枢神经调节剂的替代选择。
核心结论
- 靶向外周DRG受体的新型神经调节剂有望成为IBS疼痛治疗的新选择,并可能影响结肠传输或分泌。
研究设计与样本
- 本综述通过文献检索,评估IBS治疗未满足需求,回顾内脏传入生理学及DRG受体,并总结啮齿类模型和RCT证据。
主要发现
- 在啮齿类IBS内脏高敏感模型中,靶向DRG受体的药物可缓解疼痛或替代指标。
- DRG上表达的受体包括α-2肾上腺素能、生长抑素-SS2、5-HT3、大麻素、α4β2和α6β2烟碱型胆碱能、降钙素基因相关肽、κ-阿片和胰高血糖素样肽1受体及酸门控离子通道。
临床怎么用
- 临床可关注外周限制性神经调节剂的研发进展,作为IBS疼痛管理的潜在新选项。
局限性
- 支持证据主要来自临床前研究和人体研究,需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current management of irritable bowel syndrome (IBS) is focused on bowel dysfunction or central neuromodulators. The aims of this review were to: appraise unmet needs in IBS treatment; review the physiology of visceral afferent functions and specifically receptors in the dorsal root ganglion (DRG) cell bodies of the first order neurones; and summarize evidence of efficacy of pharmacological approaches directed at receptors expressed by DRGs based on rodent models of visceral hypersensitivity and randomized controlled trials in IBS. A literature search was done using terms identified in the aims section. The greatest need in IBS is safe treatment of pain. Physiological and noxious stimuli are conducted to the brain through vagal and pelvic parasympathetic pathways, and noxious stimuli through visceral afferents and spinal cord. Peripheral visceral afferents, with cell bodies in DRG, have receptors targeted pharmacologically to relieve pain (or surrogates) in rodent IBS models of visceral hypersensitivity. Advances in understanding mechanisms of visceral hypersensitivity lead to consideration of targeting receptors on the DRG. Those receptors on DRGs are also expressed in the central nervous system and include α-2 adrenergic, somatostatin-SS2, 5-HT3, cannabinoid, α4β2 and α6β2 nicotininc cholinergic, calcitonin gene-related peptide, κ-opioid and glucagon-like peptide 1 receptors and acid-gated ion channels. Evidence from predominantly pre-clinical and human studies supporting these peripheral targets is summarized, and provides the rationale to develop novel, peripherally restricted pharmaceuticals to reduce visceral pain in IBS. Novel neuromodulators restricted to peripheral actions and targeting DRG receptors would constitute a novel alternative to central neuromodulators for IBS pain, in addition to potential effects on colonic transit or secretion.
引用
- Camilleri M. Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation. Clin Gastroenterol Hepatol. 2026. PMID: 41974246. doi:10.1016/j.cgh.2026.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。